P H P Liberman1, M V S Goffi-Gomez2, C Schultz1, P L Jacob3, C A A de Paula4, E L Sartorato3, G T Torrezan4, E N Ferreira4, D M Carraro4. 1. Audiology Department, AC Camargo Cancer Center, r. Antonio Prudente, 211, São Paulo, 01509-900, Brazil. 2. Audiology Department, AC Camargo Cancer Center, r. Antonio Prudente, 211, São Paulo, 01509-900, Brazil. goffigomez@uol.com.br. 3. Human Molecular Genetics Laboratory, Molecular Biology and Genetic Engineering Center, CBMEG, State University of Campinas (UNICAMP), Campinas, Brazil. 4. Genomics and Molecular Biology Laboratory, International Research Center/CIPE, AC Camargo Cancer Center, São Paulo, Brazil.
Abstract
BACKGROUND AND AIM: Ototoxicity is a potential adverse effect of chemotherapy with platin drugs, such as cisplatin and carboplatin, in children. Hearing loss (HL) affecting frequencies below 4 kHz can compromise speech perception. The aim of this study was to investigate whether genetic variants previously implicated in ototoxicity are associated with HL overall and HL below 4 kHz in pediatric oncology patients treated with cisplatin or carboplatin. MATERIALS AND METHODS: Patients given cisplatin or carboplatin for a pediatric cancer at least 5 years prior to the start of the study were enrolled. The patients underwent comprehensive audiological evaluations and genotyping to detect the presence of the GJB2 c.35delG, GSTP1 c.313A>G, and MT-RNR1 m.1555A>G polymorphisms. RESULTS: HL was identified in 31/61 patients (50.8%), including 28/42 treated with cisplatin (66.6%) and 3/19 treated with carboplatin (15.8%). HL was associated with higher mean doses of cisplatin (p = .002) and carboplatin (p = .010). The c.313A>G variant of GSTP1 (heterozygous or homozygous) was detected in 31/61 patients (50.8%). An association between this variant allele and HL involving frequencies ≤ 4 kHz was identified (p = .020; 10-fold vs. non-carriers). No associations with HL were observed for GJB2 or MT-RNR1 gene variants. CONCLUSION: The GSTP1 c.313A>G variant may increase the risk of low-frequency HL in pediatric oncology patients treated with cisplatin or carboplatin chemotherapy.
BACKGROUND AND AIM: Ototoxicity is a potential adverse effect of chemotherapy with platin drugs, such as cisplatin and carboplatin, in children. Hearing loss (HL) affecting frequencies below 4 kHz can compromise speech perception. The aim of this study was to investigate whether genetic variants previously implicated in ototoxicity are associated with HL overall and HL below 4 kHz in pediatric oncology patients treated with cisplatin or carboplatin. MATERIALS AND METHODS:Patients given cisplatin or carboplatin for a pediatric cancer at least 5 years prior to the start of the study were enrolled. The patients underwent comprehensive audiological evaluations and genotyping to detect the presence of the GJB2c.35delG, GSTP1 c.313A>G, and MT-RNR1 m.1555A>G polymorphisms. RESULTS: HL was identified in 31/61 patients (50.8%), including 28/42 treated with cisplatin (66.6%) and 3/19 treated with carboplatin (15.8%). HL was associated with higher mean doses of cisplatin (p = .002) and carboplatin (p = .010). The c.313A>G variant of GSTP1 (heterozygous or homozygous) was detected in 31/61 patients (50.8%). An association between this variant allele and HL involving frequencies ≤ 4 kHz was identified (p = .020; 10-fold vs. non-carriers). No associations with HL were observed for GJB2 or MT-RNR1 gene variants. CONCLUSION: The GSTP1 c.313A>G variant may increase the risk of low-frequency HL in pediatric oncology patients treated with cisplatin or carboplatin chemotherapy.
Authors: Carmen Jerónimo; Graça Varzim; Rui Henrique; Jorge Oliveira; Maria José Bento; Cristina Silva; Carlos Lopes; David Sidransky Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-05 Impact factor: 4.254
Authors: U Peters; S Preisler-Adams; A Hebeisen; M Hahn; E Seifert; C Lanvers; A Heinecke; J Horst; H Jürgens; A Lamprecht-Dinnesen Journal: Anticancer Drugs Date: 2000-09 Impact factor: 2.248
Authors: Barna Budai; Péter Prekopp; László Noszek; Erika R Kovács; Márta Szőnyi; Dániel J Erdélyi; Krisztina Bíró; Lajos Géczi Journal: J Mol Med (Berl) Date: 2020-05-20 Impact factor: 4.599
Authors: Gladys Olivera; Luis Sendra; María José Herrero; Pablo Berlanga; Pablo Gargallo; Yania Yáñez; Andrea Urtasun; Jaime Font de Mora; Victoria Castel; Adela Cañete; Salvador F Aliño Journal: Cancer Drug Resist Date: 2019-03-19